Adjuvant intermittent chemoimmunotherapy for primary breast cancer: a prospective study with immunologic follow-up.
In an interdisciplinary prospective study 50 patients surgically treated for breast cancer were treated with six monthly courses of aggressive adjuvant chemotherapy (adriamycin and cyclophosphamide) and were randomized to receive either immunotherapy with levamisole or no additional therapy. Probability of disease-free survival for the whole group is 54.9% at 42 months. There was no noticeable difference in disease-free survival for either pre- and postmenopausal women or for patients treated with or without levamisole. The addition of levamisole had no effect on the depression of in vitro immunologic functions during chemotherapy.
D000920:Antibody-Dependent Cell Cytotoxicity; D001943:Breast Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D007978:Levamisole / Q000627:therapeutic use; D008593:Menopause; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D012397:Rosette Formation
D007978:Levamisole; D004317:Doxorubicin; D003520:Cyclophosphamide